Drug Discov Ther. 2019;13(1):38-46. (DOI: 10.5582/ddt.2019.01004)
Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction.
Sobirin MA, Herry Y, Sofia SN, Uddin I, Rifqi S, Tsutsui H
Heart failure with preserved ejection fraction (HFpEF) is a leading cause of morbidity and mortality without an established treatment. Diastolic dysfunction, the hallmark of HFpEF, is associated with altered myocardial bioenergetics. No previous study has examined the effects of coenzyme Q10 (CoQ10) on left ventricle (LV) diastolic function in patients with HFpEF. We investigated whether CoQ10 could improve LV diastolic function in patients with HFpEF. We performed a randomized controlled trial (RCT) using pretest and posttest control groups of 30 patients with HFpEF. The patients received either CoQ10 100 mg three times a day or no CoQ10 in addition to routine treatment for 30 days. Echocardiographic study was performed at baseline and follow-up. LV diastolic function was evaluated by two dimensional and Doppler echocardiography as follows; average E/e׳, septal and lateral e׳ velocity, and left atrium volume index (LAVI). A total of 28 patients completed the study. A statistically significant improvement was observed in the CoQ10 treatment group in terms of average E/e׳ (18.9 (3.8) vs. 15.1 (4.3); p < 0.01) and LAVI (32 (9) mL/m2 vs. 26 (7) mL/m2; p < 0.05) and in the control group (18.4 (3.1) vs. 15.8 (5.6); p < 0.05) and (33 (7) mL/m2 vs. 30 (8) mL/m2; p < 0.05, respectively). However, there was no difference in change reduction between groups (ΔE/e׳ ‒ 3.6 vs. ‒ 2.4; p = 0.28) and (ΔLAVI ‒ 5.4 vs. ‒ 4.4; p = 0.83). Short term CoQ10 supplementation provided no additional benefits in improving LV diastolic function in patients with HFpEF.
Full Text: 
